- Conditions
- Adult Brain Glioblastoma
- Interventions
- Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioma, Malignant, High Grade Glioma, Glioblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- OS2966, Gadoteridol
- Drug
- Lead sponsor
- OncoSynergy, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Multiple Sclerosis
- Interventions
- Gadoteridol
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more
- Conditions
- Multiple Sclerosis
- Interventions
- SAR441344 IV, placebo IV, SAR441344 SC, placebo SC, MRI contrast-enhancing preparations
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Interventions
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
- Procedure · Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- Interventions
- Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine
- Drug · Diagnostic Test
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Renal Insufficiency
- Interventions
- Not listed
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Gadolinium Retention
- Interventions
- Surgery
- Procedure
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Glioblastoma
- Interventions
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadoteridol, Magnetic Resonance Imaging
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Portland, Oregon
- Conditions
- Central Nervous System Diseases, Central Nervous System Neoplasms
- Interventions
- ProHance
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Triple Negative Breast Cancer
- Interventions
- [18F]FMISO-PET with contrast-enhanced MRI
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diagnostic Imaging, Central Nervous System Diseases
- Interventions
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadoteridol (ProHance)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Los Gatos, California + 20 more
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Indian Wells, California • Orange, California • Miami, Florida + 5 more
- Conditions
- Coronary Artery Disease, Type 1 Diabetes Mellitus
- Interventions
- Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Spinal Metastases
- Interventions
- qMRI with Gadoteridol contrast agent
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain Disease
- Interventions
- gadoteridol, gadobutrol
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Teaneck, New Jersey